Glatiramer
- Part D specialty tier in 72% of formularies (2026Q3)
- Copaxone
Therapy management checklist
Screening, baseline and ongoing monitoring with the label's stated frequency, hold and discontinue criteria, and counseling points, each quoted from the FDA label.
Loading the therapy management checklist…
Storage and cold chain
Glatiramer: storage and handling
- Refrigerate
- Yes, as the label states
Label statement
Store COPAXONE refrigerated at 2°C to 8°C (36°F to 46°F).
- Freezing
- Do not freeze
Label statement
Do not freeze COPAXONE.
- Room temperature
- up to 730 hours at or below 30°C (86°F)
Label statement
If needed, the patient may store COPAXONE at room temperature, 15°C to 30°C (59°F to 86°F), for up to one month, but refrigeration is preferred.
- Room temperature
- up to 730 hours
Label statement
If needed, the patient may store COPAXONE at room temperature, 59 o F to 86 o F (15 o C to 30 o C), for up to one month, but refrigeration is preferred.
- Back into the refrigerator
- Not addressed
- Light
- Not addressed
- Shaking
- Not addressed
All storage statements on the label (6)
- Store COPAXONE refrigerated at 2°C to 8°C (36°F to 46°F).
- If needed, the patient may store COPAXONE at room temperature, 15°C to 30°C (59°F to 86°F), for up to one month, but refrigeration is preferred.
- Do not freeze COPAXONE.
- If a COPAXONE syringe freezes, it should be discarded.
- Conditions Advise patients that the recommended storage condition for COPAXONE is refrigeration at 36 o F to 46 o F (2 o C to 8 o C).
- If needed, the patient may store COPAXONE at room temperature, 59 o F to 86 o F (15 o C to 30 o C), for up to one month, but refrigeration is preferred.
FDA label version 36, effective June 23, 2026. DailyMed
Dosing and titration calendar
Built only from the schedules the label states (loading, titration, day schedules, cycles and weight bands). Steps the label states in words the calendar cannot place are shown, not guessed.
Loading dosing schedules…
Medicare Part D coverage
5,496 Part D plans, CMS formulary files 2026Q3. Look up tier, PA, step therapy and quantity limits by plan
Patient assistance
No manufacturer program page is listed for this drug yet.
Independent foundations and the full directory (checked 2026-11-06). Eligibility and amounts are set by each program; open its page for them.
For licensed clinicians. Use with clinical judgment. Statements are quoted from the FDA label; confirm against the label for the product you are using.